
Ovid Therapeutics (OVID) Stock Forecast & Price Target
Ovid Therapeutics (OVID) Analyst Ratings
Bulls say
Ovid Therapeutics is a promising biopharmaceutical company with potential first-in-class and best-in-class drugs in its pipeline, targeting severe epileptic neurological disorders with multi-billion dollar market opportunities. The recent KCC2 R&D event showcased additional preclinical data and a detailed clinical roadmap for OV4071 and OV329, while the company's balance sheet strength and cash runway provide a solid foundation for future development. With multiple upcoming readouts and potential for expanded indications, Ovid remains a top pick with potential upside to current projections.
Bears say
Ovid Therapeutics is dedicated to developing novel therapeutics for epilepsy disorders, with their most advanced program being OV329, which is advancing to Phase 2 studies. With revenue potential projected at over $6B, Ovid is exploring multiple potential therapeutic applications for OV4071, including schizophrenia and psychoses, and is advancing next-generation KCC2 activators from its proprietary library of compounds. However, without clinical data to support its effectiveness and concerns about potential prolonged drug effects, there is high risk and potential for setbacks, leading to a negative outlook for the stock.
This aggregate rating is based on analysts' research of Ovid Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Ovid Therapeutics (OVID) Analyst Forecast & Price Prediction
Start investing in Ovid Therapeutics (OVID)
Order type
Buy in
Order amount
Est. shares
0 shares